Page 338 - Vitamin D and Cancer

14 Unique Features of the Enzyme Kinetics for the Vitamin D System 325

27. Neale RE, Youlden DR, Krnjacki L, Kimlin MG, van der Pols JC (2009) Latitude variation in
pancreatic cancer mortality in Australia. Pancreas 38(4):387–390
28. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T et al
(2010) Association between pre-diagnostic circulating vitamin D concentration and risk of
colorectal cancer in European populations:a nested case-control study. BMJ 340:b5500
29. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G et al (2004) Both high
and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longi-
tudinal, nested case-control study in the Nordic countries. Int J Cancer 108(1):104–108
30. Vieth R (2004) Enzyme kinetics hypothesis to explain the U-shaped risk curve for prostate
cancer vs 25-hydroxyvitamin D in nordic countries. Int J Cancer 111(3):468
31. Vieth R, Choo R, Deboer L, Danjoux C, Morton G, Klotz L (2006) Rise in prostate-specific
antigen in men with untreated low-grade prostate cancer is slower during spring-summer. Am
J Ther 13(5):394–399
32. Woo TC, Choo R, Jamieson M, Chander S, Vieth R (2005) Pilot study: potential role of vita-
min D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer
51(1):32–36
33. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT
(2009) Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and
ovarian screening trial. Cancer Res 69(4):1439–1447
34. Vieth R, McCarten K, Norwich KH (1990) Role of 25-hydroxyvitamin D3 dose in determin-
ing rat 1, 25- dihydroxyvitamin D3 production. Am J Physiol 258(5 Pt 1):E780–E789
35. Vieth R, Milojevic S, Peltekova V (2000) Improved cholecalciferol nutrition in rats is noncal-
cemic, suppresses parathyroid hormone and increases responsiveness to 1, 25-dihydroxyc-
holecalciferol. J Nutr 130(3):578–584
36. Vieth R, Milojevic S (1995) Moderate vitamin D3 supplementation lowers serum 1, 25-dihy-
droxy-vitamin D3 in rats. Nutr Res 15(5):725–731
37. Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R (2008) Comparison of daily,
weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip
fracture patients. J Clin Endocrinol Metab 93(9):3430–3435
38. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN et al (2004) The
prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone
and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis
25(6):967–971
39. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D et al (2000)
Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate
oncogene. Nat Genet 25(2):144–146
40. Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M et al (2004) Clinical
significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer.
Ann Oncol 15(2):236–241
41. Farhan H, Wahala K, Cross HS (2003) Genistein inhibits vitamin D hydroxylases CYP24 and
CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 84(4):423–429
42. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG (2003) Evaluation of vitamin
D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res 164:273–288
43. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD et al (2004) Molecular activ-
ity of 1, 25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells
revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92(3):131–141
44. Chen TC (2008) 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of
tumor suppressor in the prostate. Anticancer Res 28(4A):2015–2017
45. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D, Peehl DM (2004) Mechanisms of
decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol
221(1–2):67–74
46. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL et al
(2002) 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate
cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol
81(2):135–140